A compound including a first ligand L.sub.A of Formula I,

##STR00001##

is described. In Formula I, each of X.sup.1 to X.sup.9 is independently C or N; one of Z.sup.1 and Z.sup.2 is C and the other is N; each of K.sup.1 and K.sup.2 is independently a direct bond, O, or S; at least one of K.sup.1 and K.sup.2 is a direct bond; at least one R.sup.B is not hydrogen; R.sup.3 is selected from alkyl, heteroalkyl, cycloalkyl, and heterocycloalkyl; L.sub.A is coordinated to a metal M; at least one of the following is true: (i) at least one R.sup.B comprises a 5- or 6-membered, (ii) two adjacent R.sup.B are joined to form a fused 5- or 6-membered ring, or (iii) R.sup.B comprises a carbocyclic or heterocyclic ring substituted with at least one electron withdrawing group. Devices, consumer products, and formulations including the compound are also described.

To develop a compound which is highly accumulated in cancer cells and capable of emitting an α-ray and provide a pharmaceutical composition for cancer treatment including the compound.

A pharmaceutical composition for cancer treatment including a compound having a structure in which .sup.211At is introduced as a substituent into an amino acid derivative having an affinity with an amino acid transporter LAT1 or a pharmaceutically acceptable salt of the compound.

The present invention relates to a gadolinium-based compound of a Chemical Formula 1, a method for producing the same, and an MRI contrast agent containing the same. [Chemical Formula 1] [structural formula] In chemical formula 1, A and Linker represent linking groups, and RB represents a Rose Bengal-derived part.

A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R.sup.0 is O or S. Each of R.sup.1a, R.sup.1b and R.sup.1c may be —CO.sub.2H, —SO.sub.2H, —SO.sub.3H, —PO.sub.2H, or —PO.sub.3H.sub.2, for example. R.sup.2 may be methylene or a derivative thereof, propylene or a derivative thereof, or a derivative of ethylene, optionally substituted. R.sup.3 is a linker. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases/conditions. ##STR00001##

Provided are an organic electroluminescent material and a device comprising the same. The organic electroluminescent material is a metal complex comprising a ligand L.sub.a having a structure of Formula 1A and a ligand L.sub.b having a structure of Formula 1B. Such new types of compound can be applied to an electroluminescent device to improve luminescence performance, efficiency or a lifetime of the device, exhibit more saturated luminescence and significantly improve overall performance of the device. Further provided are an electroluminescent device comprising the metal complex and a compound composition comprising the metal complex.

Reagents and methods for labeling biomolecules with astatine isotopes in higher oxidation states. The reagents and methods allow for efficient labeling of biomolecules, such as antibodies, without the formation of high molecular weight by products that arise due to .sup.211At-promoted dimerization and higher aggregation of the conjugated biomolecules, and diminish cellular retention of astatine caused by cellular oxidization of the bonded astatine atom in vivo.

##STR00001##

Disclosed herein is a salt of formula I: where R.sup.1, X, n, R, R.sup.1, Y, m, p, q, Z and o are as defined herein. Also disclosed herein are methods of using said salts in chemical synthesis, such as to prepare compounds isotopically enriched in 18F for use in PET & imaging, as well as methods to make the compounds of formula I.

Excessive deposition of extracellular matrix is a hallmark of Idiopathic pulmonary fibrosis (IPF), it is advantageous to target the cells and the mechanisms associated with this process. By targeting myofibroblasts (specialized contractile fibroblasts) that are key for the development of IPF with drugs conjugated with fibroblast activation protein (FAP). this technology helps minimize the production of extracellular matrix in the lungs and provides a new treatment option for patients diagnosed with IPF.

Provided are compounds of formula Ir(L.sub.A).sub.x(L.sub.B).sub.y(L.sub.C).sub.z wherein the L.sub.A ligand has the Formula I

##STR00001## that are useful as phosphorescent emitters in OLEDs. Also provided are formulations comprising these compounds. Further provided are OLEDs and related consumer products that utilize these compounds.

Provided are organometallic compounds. Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.